Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Short-term Investments (2024 - 2026)

Corvus Pharmaceuticals' Short-term Investments history spans 3 years, with the latest figure at $196.6 million for Q1 2026.

  • Quarterly Short-term Investments changed N/A to $196.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $196.6 million through Mar 2026, changed N/A year-over-year, with the annual reading at $52.2 million for FY2025, 20.71% up from the prior year.
  • Short-term Investments came in at $196.6 million for Q1 2026, up from $52.2 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $196.6 million in Q1 2026 to a low of $43.2 million in Q4 2024.
  • The 3-year median for Short-term Investments is $52.2 million (2025), against an average of $97.3 million.
  • The largest YoY upside for Short-term Investments was 20.71% in 2025 against a maximum downside of 20.71% in 2025.
  • Corvus Pharmaceuticals' Short-term Investments stood at $43.2 million in 2024, then grew by 20.71% to $52.2 million in 2025, then surged by 276.84% to $196.6 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Short-term Investments are $196.6 million (Q1 2026), $52.2 million (Q4 2025), and $43.2 million (Q4 2024).